
Colorized scanning electron micrograph of mpox virus particles (blue) on the surface of infected VERO E6 cells (pink). NIAID
A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona.